Vortex Biotech managing director Paul Reeves talked with Proactive's Stephen Gunnion about the company’s expansion into Manchester and the opening of its new advanced laboratory.
Reeves described Vortex, an EMV Capital (AIM:EMVC, FRA:NTK1) porfolio company, as a precision oncology company enabling access to intact circulating tumour cells (CTCs) for clinicians, researchers and pharmaceutical companies. He said the Manchester site will significantly enhance the company’s capabilities, particularly in clinical validation and commercial rollout.
Reeves highlighted three main advantages of the new facility: increased capacity, proximity to research partners and hospitals, and access to a vibrant innovation ecosystem. He said, “We’re surrounded by the partners that we need in terms of universities, hospitals... and researchers that we want to tap into.”
Discussing market timing, Reeves pointed to growing momentum in liquid biopsy technology. He explained how Vortex’s CTC platform complements the more established ctDNA approach, combining for deeper insight into cancer diagnosis, treatment resistance and patient monitoring.
The company’s roadmap includes multicenter validation studies across major cancer types and the launch of clinical trial services. Reeves noted that supplying high-purity CTCs will be a “key revenue-generating channel for Vortex” and that biomarker assay development is underway to support early detection and therapy selection.
Vortex is building towards a broader commercial rollout in the UK and Europe, starting with research and clinical trial markets, then moving into regulated diagnostics.
Visit Proactive’s YouTube channel for more in-depth interviews. Don’t forget to like this video, subscribe, and turn on notifications for future updates.
#VortexBiotech #LiquidBiopsy #CancerDiagnostics #CirculatingTumorCells #OncologyInnovation #BiotechNews #PrecisionMedicine #ClinicalTrials #CancerResearch #ctDNA #ManchesterBiotech #EMVCapital
